visceral leishmaniasis - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

RGD DISEASE ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.

Term:	visceral leishmaniasis	go back to main search page
Accession:	DOID:9146	browse the term
Definition:	A leishmaniasis that is the most severe form of the disease caused by protozoan parasites of the Leishmania genus, resulting in the infection of the internal organs such as liver, spleen and bone marrow. The symptoms include fever, weight loss, and an enlarged spleen and liver. (DO)
Synonyms:	exact_synonym:	black fever; infection by visceral leishmaniasis; kala azar
	related_synonym:	KAZA1; KAZA2; KAZA3; kala azar, susceptibility to, 1; kala azar, susceptibility to, 2; kala azar, susceptibility to, 3; visceral leishmaniasis, susceptibility to, 1; visceral leishmaniasis, susceptibility to, 3
	xref:	EFO:0005045; ICD10CM:B55.0; ICD9CM:085.0; MESH:D007898; MIM:608207; MIM:611381; MIM:611382; MIM:PS608207; MONDO:0005445; NCI:C34771

show annotations for term's descendants Sort by:
Rat (34) Mouse (35) Human (38) Chinchilla (25) Bonobo (31) Dog (35) Squirrel (26) Pig (33) Green Monkey (31) Naked Mole-rat (28) All
Genes (34)

visceral leishmaniasis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

activation-induced cytidine deaminase

mRNA:altered expression:Bcell,CD4Tcell

RGD

NCBI chr 4:155,774,132...155,783,972
Ensembl chr 4:155,774,132...155,783,972

G

C-C motif chemokine ligand 4

protein:increased expression:serum

RGD

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine receptor 2

associated with Malnutrition;mRNA:increased expression:lymph node,spleen:

RGD

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

C-C motif chemokine receptor 3

protein:increased expression:blood, T cell

RGD

NCBI chr 8:123,586,100...123,634,178
Ensembl chr 8:123,616,236...123,634,990

G

C-C motif chemokine receptor 5

treatment

RGD

NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260

G

CD163 molecule

exacerbates

protein:increased expression:blood serum (human)

RGD

NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878

G

CD40 molecule

treatment

RGD

NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534

G

CD40 ligand

RGD

NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306

G

C-reactive protein

CTD Direct Evidence: marker/mechanism

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

colony stimulating factor 2

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:17404324 PMID:8035028

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

C-X-C motif chemokine ligand 10

mRNA:increased expression:liver

RGD

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

heme oxygenase 1

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:22461696 PMID:23729024

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

interferon gamma

treatment

CTD Direct Evidence: therapeutic

CTD
RGD

PMID:1901333 PMID:7854095 PMID:3104456 PMID:27999013

RGD:8158041, RGD:40890273

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:15716043 PMID:17404324 PMID:22461696 PMID:29745990

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 10 receptor subunit alpha

CTD Direct Evidence: therapeutic

NCBI chr 8:45,563,009...45,578,041
Ensembl chr 8:45,563,137...45,578,061

G

interleukin 18

susceptibility

RGD

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

CTD Direct Evidence: marker/mechanism

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 27

mRNA, protein:increased expression:spleen, liver (mouse)

RGD

NCBI chr 1:181,173,108...181,178,720
Ensembl chr 1:181,173,372...181,178,582

G

interleukin 2 receptor subunit beta

susceptibility

DNA:polymorphisms:exon:8777, 8838(human)

RGD

NCBI chr 7:110,033,341...110,048,054
Ensembl chr 7:110,033,341...110,048,054

G

interleukin 6

CTD Direct Evidence: marker/mechanism

PMID:7554475 PMID:17404324 PMID:22461696

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interferon regulatory factor 5

protein:increased expression:CD4 T cell, nucleus

RGD

PMID:32038622 PMID:30067973

RGD:40924560, RGD:40924629

NCBI chr 4:58,127,577...58,140,665
Ensembl chr 4:58,127,640...58,139,267

G

lymphotoxin alpha

severity

DNA:polymorphisms

RGD

PMID:12438370 PMID:15579454

RGD:8548784, RGD:8548789

NCBI chr20:3,618,853...3,621,324
Ensembl chr20:3,618,853...3,620,859

G

lymphotoxin beta

RGD

NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381

G

mannose binding lectin 2

disease_progression
susceptibility

DNA:polymorphism:promoter:
DNA:SNPs,haplotype:promoter,exon:
protein:increased expression:serum:

RGD

PMID:17357060 PMID:17357060 PMID:22995279 PMID:26297290 PMID:26297290

RGD:8693721, RGD:8693721, RGD:8693726, RGD:11522692, RGD:11522692

NCBI chr 1:228,016,439...228,024,736

G

microRNA 155

RGD

NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718

G

microRNA 21

treatment

RGD

NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348

G

NFE2 like bZIP transcription factor 2

treatment

RGD

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta

treatment

RGD

NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930

G

RT1 class II, locus Ba

susceptibility

CTD Direct Evidence: marker/mechanism
DNA:SNP:enhancer: (rs9271858) (human)

CTD
RGD

PMID:23291585 PMID:23291585

NCBI chr20:4,575,134...4,579,727
Ensembl chr20:4,575,134...4,579,744

G

RT1 class II, locus Db1

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258

G

solute carrier family 11 member 1

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16597321 PMID:17067929

NCBI chr 9:75,957,193...75,968,115
Ensembl chr 9:75,957,316...75,968,101

G

signal transducer and activator of transcription 4

RGD

NCBI chr 9:49,472,660...49,588,540
Ensembl chr 9:49,419,340...49,588,540

G

toll-like receptor 2

disease_progression

RGD

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

tumor necrosis factor

severity

DNA:polymorphisms
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:1901333 PMID:22461696 PMID:12438370 PMID:15579454

RGD:8548784, RGD:8548789

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

Term paths to the root

Path 1
Term	Annotations
disease	19099
disease of anatomical entity	18440
endocrine system disease	7029
liver disease	3007
visceral leishmaniasis	34
Path 2
Term	Annotations
disease	19099
disease of anatomical entity	18440
nervous system disease	14334
Neurologic Manifestations	10420
sensory system disease	7331
skin disease	4309
Infectious Skin Diseases	305
Parasitic Skin Diseases	71
leishmaniasis	65
visceral leishmaniasis	34

paths to the root